Abstract
Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1-5 In this article, the authors consider the significance of the GLP-1 path-way in the management of T2DM, and some of the advantages of incretin-based therapy.
Original language | English |
---|---|
Pages (from-to) | 18-28 |
Number of pages | 11 |
Journal | Future Prescriber |
Volume | 9 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2008 |
Keywords
- diabetes
- medical care
- non-insulin-dependent diabetes
- glucose
- metabolism